Causing another reiteration by Aschoff. Stock price get hammered as this POI result was widely expected, and is somewhat offset by the nice but vague oral result. Where the heck are the numbers for the oral P2? Gonna save 'em, so somebody will listen to their scientists make a presentation at an upcoming scientific meeting, no doubt. Guess Wyeth is calling the shots and keeping the cards close to its vest in true big pharma fashion.
But stat sig is stat sig, though 122 patients isn't a huge number. That's why I'd like to see the p value and such.
Well, watching for possible re-entry, anyhow. Methinks that's most of the clinical risk for PGNX for a while. Now it's all about earnings (unless I've forgotten something imminent with PRO-140, which is an interesting drug, but being an injectable, will not be a blockbuster).
Suspect the overall market is about to do something violent, and not in a good way. Will probably take PGNX part way with it. Might be good bottom fishing this summer, but better reel 'em in fast.
Cheers, Tuck |
